Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation (original) (raw)
References
Atkinson K, Biggs JC, Ting A, Concannon AJ, Dodds AJ, Pun A (1982) Cyclosporin A is associated with faster engraftment and less mucositis than methotrexate after allogenic bone marrow transplantation. Br J Haematol 53: 265–270 Google Scholar
Bortin MM (1983) Pathogenesis of interstitial pneumonitis following allogenic bone marrow transplantation for acute leukemia. In: Gale RP (ed) Recent advances in bone marrow/transplantation. Allan R. Liss, New York, pp 445–460 Google Scholar
Deeg HJ, Torok-Storb B, Storb R, Weiden PL (1980) Effect of cyclosporin A (CyA) on marrow engraftment in vivo and on hematopoiesis in vitro. Exp Hematol 8: 78 (abstract 138) Google Scholar
Deeg HJ, Storb R, Thomas ED, Kennedy MS, Fluornoy N, Buckner CD, Clift R, Doney K, Sale G, Sanders J, Witherspoon R (1983) Marrow transplantation for acute nonlymphoblastic leukemia in first remission: preliminary results of a randomized trial comparing cyclosporin and methotrexate for the prophylaxis of graft-versus-host disease. Transplant Proc 15: 1385–1389 Google Scholar
Gale RP, Kay HEM, Rimm AA, Bortin MM (1982) Bonemarrow transplantation for acute leukemia in first remission. Lancet II: 1006–1009 Google Scholar
Gratwohl A, Bull M, Graw R Jr, Norton L, Knutsen T (1978) Methotrexate and citrovorum factor after histoincompatible allogenic bone marrow transplants in dogs. Acta Hematol 60: 233–242 Google Scholar
Hows JM, Kaffaf S, Palmer S, Harris R, Fairhead S, Gordon-Smith EC (1982) Regeneration of peripheral blood cells following allogenic bone marrow transplantation for severe aplastic anemia. Br J Haematol 52: 551–556 Google Scholar
Jolivet J, Cowan K, Curt G, Clendeninn N, Chabner B (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094–1104 Google Scholar
Lazarus HM, Coccia PF, Herzig RH, Graham-Pole J, Gross S, Strandjord S, Gordon E, Cheung NKV, Warkentin PI, Spitzer TR, Warm SE (1984) Incidence of acute graft-versus host disease with and without methotrexate prophylaxis in allogenic bone marrow transplant patients. Blood 64: 215–220 Google Scholar
Martin PJ, Hansen JA, Buckner CD (1985) Effects of in vivo depletion of T cells in HLA-identical allogenic marrow grafts. Blood 66: 664–672 Google Scholar
Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett A, Jameson B, Sloane J, Lawler SD, Kay Hem, Lawson D, McElwain TJ, Alexander P (1980) Cyclosporin A to prevent graft versus host disease in man after allogenic bone-marrow transplantation. Lancet I: 327–329 Google Scholar
Prentice HG, Blacklock HA, Janossy G, Bradstock KJ, Skeggs D, Goldstein G, Hoffbrand AV (1982) Use of anti-T-cell monoclonal antibody OKT 3 to prevent acute graftversus-host disease in allogenic bone marrow transplantation for acute leukemia. Lancet I: 700–703 Google Scholar
Ramsay NKC, Kersey JH, Robinson LL, McGlave PB, Woods WG, Krivit W, Kim TH, Goldman AI, Nesbit ME Jr (1982) A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306: 392–397 Google Scholar
Ringden O, Zwaan F, Hermans J, Gratwohl A (1987) European experience of bone marrow transplantation for leukemia. Transplant Proc 19: 2600–2604 Google Scholar
Storb R (1984) Pathophysiology and prevention of graft-versus-host disease in: Mc Cullough J, Saudler SG (eds): Advances in Immunobiology: Blood Cell Antigens and Bone Marrow Transplantation. Allan R. Liss, New York, pp 337–366 Google Scholar
Storb R, Graham T, Shiruba R, Thomas E (1970) Treatment of canine graft-versus-host disease with methotrexate and cyclophosphamide following bone marrow transplantation from histoincompatible donors. Transplantation 10: 165–169 Google Scholar
Storb R, Rudolph R, Kolb H, Graham T, Mickelson E, Erickson V, Lerner K, Kolb H, Thomas E (1973) Marrow grafts between DLA-matched canine littermates. Transplantation 15: 92–100 Google Scholar
Storb R, Thomas E, Buckner C, Clift R, Johnson F, Fefer A, Glucrsberg H, Giblett E, Lerner K, Neiman P (1974) Allogenic marrow grafting for treatment of aplastic anemia. Blood 43: 157–180 Google Scholar
Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA, Clift RA, Doney KC, Flournoy N, Kennedy MS, Loughran TP, Mc Guffin RW, Sale GR, Sanders JE, Singer JW, Stewart PS, Sullivan KM, Witherspoon RP (1985) Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporin versus methotrexate for prophylaxis of graft-versus-host disease. Blood 66: 698–702 Google Scholar
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED (1986) Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314: 729–735 Google Scholar
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone marrow transplantation. N Engl J Med 292: 832–843 Google Scholar
Tutschka PJ, Farmer E (1981) Therapy of acute graft-versus-host disease (GVHD — Baltimore experience. Exp Hematol [Suppl 9] 9: 126 Google Scholar
Tutschka PJ, Beschorner WE, Hess AD, Santos GW (1983) Cyclosporin A to prevent graft versus host disease: a pilot study in 22 patients receiving allogenic marrow transplants. Blood 61: 318–325 Google Scholar
Zwaan FE, Hermans J (1982) For the EBMT Leukemia Working Party Bone Marrow Transplantation for leukemia — European results in 264 cases. Exp Hematol [Suppl 10] 10: 64 Google Scholar
Zwaan FE, Hermans J (1983) Report of the EBMT Leukemia Working party. Exp Hematol [Suppl 13] 11: 3 Google Scholar